Aurobindo Pharma Ltd's Q3FY25 Quarter Results
- 07 Feb 2025
Result Summary
- Aurobindo Pharma Ltd reported a 2.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 8.3%.
- Its expenses for the quarter were up by 3.2% QoQ and 11.0% YoY.
- The net profit increased 3.5% QoQ and decreased 10.0% YoY.
- The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 14.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 8135.81 | 7932.07 | 7514.30 | 2.6% | 8.3% |
Total Expenses | 6937.55 | 6724.91 | 6249.29 | 3.2% | 11.0% |
Profit Before Tax | 1198.26 | 1207.16 | 1265.01 | -0.7% | -5.3% |
Tax | 354.28 | 390.51 | 322.45 | -9.3% | 9.9% |
Profit After Tax | 845.57 | 816.95 | 939.97 | 3.5% | -10.0% |
Earnings Per Share | 14.60 | 14.00 | 16.00 | 4.3% | -8.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aurobindo Pharma Ltd is a major pharmaceutical company that operates in the healthcare industry. The company is known for manufacturing a wide range of pharmaceutical products, including generic medications, active pharmaceutical ingredients (APIs), and branded formulations. Aurobindo Pharma has a significant presence in both the domestic and international markets, with a broad portfolio that covers various therapeutic segments such as antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-allergics. As a company listed on the stock exchange, Aurobindo Pharma is subject to regular financial reporting and market scrutiny. There have been no specific recent developments provided in the data; therefore, any recent strategic moves or changes in business operations remain undisclosed.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Aurobindo Pharma Ltd reported a total income of ₹8135.81 crores. This marks a quarter-over-quarter (QoQ) increase of 2.6% from the previous quarter (Q2FY25), which recorded a total income of ₹7932.07 crores. Additionally, the year-over-year (YoY) growth from Q3FY24, where the total income was ₹7514.30 crores, is 8.3%. This consistent increase in total income over both the quarters and the previous year indicates a positive trajectory in the revenue stream for the company. The income growth reflects the company's capability to generate higher sales or other income sources in the current quarterly period compared to the past periods.
Profitability
Aurobindo Pharma Ltd's profitability metrics for Q3FY25 show a mixed performance. The company registered a profit before tax of ₹1198.26 crores, a slight decline of 0.7% from the previous quarter's figure of ₹1207.16 crores. Year-on-year, there is a 5.3% decrease from the Q3FY24 figure of ₹1265.01 crores. After accounting for taxes, the profit after tax stood at ₹845.57 crores in Q3FY25, which reflects a 3.5% increase from ₹816.95 crores in Q2FY25. However, comparing it to the same quarter last year, there is a 10.0% decline from ₹939.97 crores. The earnings per share (EPS) for Q3FY25 was ₹14.60, which is a 4.3% increase from Q2FY25's ₹14.00, yet an 8.8% decrease from the ₹16.00 reported in Q3FY24. These figures suggest fluctuations in profitability despite the overall revenue increase.
Operating Metrics
Aurobindo Pharma Ltd's operating expenses, as captured in the total expenses for Q3FY25, amounted to ₹6937.55 crores. This represents a QoQ rise of 3.2% from ₹6724.91 crores in Q2FY25 and an 11.0% YoY increase from ₹6249.29 crores in Q3FY24. These rising expenses indicate higher operational costs over both the recent quarter and the previous year. The tax expense for Q3FY25 was ₹354.28 crores, showing a significant QoQ decrease of 9.3% from ₹390.51 crores in Q2FY25, but a 9.9% increase from the ₹322.45 crores in Q3FY24. These changes in the tax line item could be reflective of variations in tax liabilities or other fiscal policies affecting the company. The data provided does not include specific details on financial ratios, such as the P/E ratio, debt-to-equity ratio, or current ratio, thus those aspects remain uncalculated in this report.
